What Vitazi.ai does

Vitazi.ai, Inc. is a privately held Delaware-incorporated healthcare technology company (DBA "VITAZI AI") founded in 2021 by Dr. Jeremy Stueven, a board-certified emergency physician. The company operates a cloud-based, vendor-neutral ophthalmic imaging platform anchored by the Vitazi Image Hub, which routes Provider Portals, Patient Portals, Workflow Support with clinical notation, and a Life Sciences Dashboard into a single imaging data layer that interoperates with existing DICOM-capable retinal imaging devices. Its product suite spans Vitazi-MD (connected retinal imaging and specialist collaboration across primary care, retail health, and integrated health systems), Vitazi-DR (an autonomous diabetic retinopathy screening solution under clinical evaluation with international deployment initiatives), and an IDx-DR integration for autonomous screening, with compliance posture covering HIPAA, SOC 2, and FDA 21 CFR Part 11 alignment.

The platform applies computer vision to retinal fundus images to detect diabetic retinopathy, age-related macular degeneration, and glaucoma, and extends into oculomics—using retinal biomarkers to flag systemic conditions including Alzheimer's, Parkinson's, traumatic brain injury, and hypertensive emergency. Business model is enterprise SaaS subscription for the platform and modules, complemented by life sciences data access partnerships (population-scale cohort discovery and biomarker exploration via the Life Sciences Dashboard) and strategic co-development licensing, exemplified by the April 2026 alliance with Circular Genomics to combine retinal imaging with circRNA blood biomarkers for an Alzheimer's diagnostic workflow. Go-to-market is enterprise field sales with quote-based pricing, inside-sales phone support, channel partnerships with eye care and clinical networks, and co-marketing via the VSP Vision relationship following the 2025 VSP Vision Innovation Challenge win.

Vitazi.ai is backed by KickStart Fund and Tramway Venture Partners across disclosed funding rounds totaling approximately $2.15M, with additional undisclosed capital closed in February 2025. Customer segmentation is deliberately diversified across eye care providers, integrated health systems, primary care, retail healthcare, pharmaceutical and life sciences organizations, academic researchers, and AI developers, while the company itself remains at sub-10-employee scale with offices in San Diego (headquarters per the company website), Scottsbluff, Santa Fe, and a registered/legal address in Fort Collins.

Name

Vitazi.ai

Legal name

Vitazi.AI, Inc.

Website

https://vitazi.ai

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Vitazi.ai develops a cloud-based, vendor-neutral ophthalmic imaging platform with AI-powered retinal analysis for early detection of diabetic, cardiovascular, and neurodegenerative diseases, serving eye care providers, integrated health systems, primary care, retail healthcare, and pharmaceutical and life sciences organizations.

Ownership category

akta.pro rank

Product category

Ophthalmic Imaging Software

NAICS

Custom Computer Programming Services (541511), Diagnostic Imaging Centers (621512)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industries

Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Virtual Nursing, Telemonitoring & Command Center Platforms (HLACAFAH)

Keywords

• Ophthalmic imaging platform
• Retinal screening software
• AI retinal analysis
• Teleretinal workflow
• Oculomics diagnostics

Headquarters

HQ city

Santa Fe

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Subscription/SaaS: Cloud-based platform licensing model providing access to Vitazi Image Hub, Vitazi-MD, and associated workflow tools. Subscription-based pricing with tiered access levels for different organizational sizes and use cases.
2. Life Sciences & Research Data Services: Structured ophthalmic imaging dataset access for pharma companies, researchers, and AI developers enabling discovery at population scale. Revenue generated through data access partnerships and research collaborations.
3. Strategic Partnership Licensing: Co-development partnerships with companies like Circular Genomics for multimodal diagnostic workflows combining AI retinal imaging with molecular biomarkers, potentially creating licensing and collaboration revenue streams.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Vitazi.ai provides a cloud-based, vendor-neutral ophthalmic imaging platform (Vitazi Image Hub) that connects provider portals, patient portals, workflow tools, and a Life Sciences Dashboard into a single imaging data layer. Its core commercial product, Vitazi-MD, delivers connected retinal imaging and specialist collaboration workflows across primary care, integrated health systems, retail healthcare, and eye care practices, with AI-enabled screening (including Vitazi-DR for diabetic retinopathy) and oculomics-based detection of systemic disease. The platform integrates with existing DICOM imaging hardware via Universal DICOM protocol support and is offered on an enterprise subscription basis.

Product overview

Vitazi.ai offers a unified platform-plus-modules architecture anchored by the Vitazi Image Hub™, a cloud-native, vendor-neutral ophthalmic imaging platform that serves as the central operating layer connecting all products and modules. The platform is designed to unify retinal imaging workflows across devices and healthcare environments. The primary clinical product is Vitazi-MD™, a connected retinal imaging and specialist collaboration platform that enables cloud-based image acquisition, ophthalmic review, and diagnostic reporting workflows. Vitazi-DR™ is an autonomous retinal imaging solution under clinical evaluation for diabetic retinopathy screening. The platform includes modular components — Patient Portal (for patient access, scheduling, referrals, and secure chat), Provider Portal (for streamlined clinical workflow and notation), Life Sciences Dashboard (for population-level research and cohort discovery), and Workflow Support tools — all routing through the Vitazi Image Hub as the unified data layer. An IDx-DR integration provides autonomous diabetic retinopathy screening capability within the platform ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

• Vitazi Image Hub Cloud-native, vendor-neutral ophthalmic imaging platform that serves as the central hub for storing, organizing, comparing, analyzing, and sharing retinal imaging data across eye care ecosystems. Connects provider portals, patient portals, workflow support, and life sciences dashboard under a single source of truth for imaging data, with Universal DICOM protocol support and vendor-neutral device compatibility.
• Vitazi-MD Connected retinal imaging and specialist collaboration platform enabling cloud-based retinal imaging review, ophthalmic collaboration, and scalable clinical workflow coordination across primary care environments, retail healthcare settings, integrated health systems, and clinical care networks. Supports image acquisition, ophthalmic review, and diagnostic reporting workflows with integrated EHR interoperability.
• Vitazi-DR Autonomous retinal imaging solution designed to support scalable diabetic retinopathy screening operations. Currently undergoing clinical evaluation and international deployment initiatives.
• Life Sciences Dashboard Structured ophthalmic imaging dataset interface connecting pharmaceutical companies, researchers, academics, AI developers, and health organizations to population-level retinal insights for cohort discovery, biomarker exploration, therapy monitoring, and clinical research. Generates revenue through data-access partnerships and research collaborations.

Quantifiable outcome

• Reduced administrative burden: minutes healthcare providers may spend on administrative and EHR-related tasks for every 60 minutes of direct patient care
• +1 more outcomes

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• Circular GenomicscoreStrategic or Co-development Partner · 29 April 2026Strategic alliance to co-develop multimodal diagnostic workflow combining AI-powered retinal imaging with proprietary circular RNA (circRNA) blood biomarkers for early detection and risk stratification of Alzheimer's disease. Two-step clinical process: non-invasive retinal imaging for population-level screening followed by blood-based circRNA molecular confirmation. Partnership aims to accelerate market penetration for both platforms while creating strategic value for healthcare systems, pharmaceutical partners, and payers through improved patient identification for emerging disease-modifying therapies.
• VSP VisionflagshipGTM or Marketing PartnerVSP Vision Innovation Challenge winner and featured partner on VSP Vision's Future of Oculomics and Futurist Report. Strategic marketing partnership providing visibility within the VSP Vision network of eye care providers and recognition as an innovative ophthalmic imaging solution.
• Lerner Venture LawminorOthersLegal advisor providing legal counsel on venture financing, corporate matters, and intellectual property. Alan Nolley, Jr., JD serves as Chief Administrative Officer with background in business law.
• Sheppard & MullinminorOthersHealthcare and telehealth law advisory firm providing legal counsel on regulatory compliance, healthcare law, and telehealth regulations.
• Imaging Device ManufacturerscoreTechnology or IntegrationVendor-neutral platform supports integration with DICOM-capable ophthalmic imaging devices from multiple manufacturers. Enables healthcare organizations to leverage existing imaging hardware without rip-and-replace requirements.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Heidelberg Engineering: Heidelberg Engineering manufactures premium ophthalmic imaging systems (SPECTRALIS OCT, HRT) used in retinal disease diagnosis. While primarily a device company, its HEYEX image management software competes in the eye care informatics layer where Vitazi.ai's Image Hub also operates.
• Topcon Healthcare: Topcon is a major manufacturer of ophthalmic imaging devices (fundus cameras, OCT) and offers the Harmony healthcare IT platform for image management. As a vendor-neutral platform, Vitazi.ai must integrate with Topcon devices but Topcon's broader portfolio positions it as a large incumbent in the eye care ecosystem.
• Optos (Nikon): Optos, owned by Nikon, produces ultra-widefield retinal imaging devices deployed globally in eye care practices. Its imaging hardware generates the kind of data Vitazi.ai's Image Hub is designed to store and analyze, making it a key complementary — and potentially competitive — ecosystem player.
• Carl Zeiss Meditec: Carl Zeiss Meditec is a global leader in ophthalmic devices and diagnostic imaging, including fundus imaging, OCT, and surgical microscopy. Its broad portfolio and FORUM eye care data management platform position it as a large incumbent that Vitazi.ai must integrate with rather than displace.

Direct peers

• Eyenuk: Eyenuk's EyeArt is an FDA-cleared AI system for autonomous DR screening widely deployed in primary care and retail pharmacy settings. It is a direct competitor in the AI-enabled retinal disease detection category Vitazi.ai targets with Vitazi-DR.
• AEYE Health: AEYE Health provides FDA-cleared autonomous AI for diabetic retinopathy screening (AEYE-DS) with a focus on single-image, portable workflow suitable for primary care and retail clinics. It competes with Vitazi-DR in the same target customer segments.
• Digital Diagnostics: Digital Diagnostics developed IDx-DR, the first FDA-cleared autonomous AI for diabetic retinopathy detection. Vitazi.ai actually integrates IDx-DR into its platform, making it both a technology partner and direct competitor in autonomous retinal screening workflows serving primary care and integrated health systems.

Emerging players

• Retina-AI Health: Retina-AI Health develops AI-based screening for diabetic retinopathy and other retinal conditions, with a focus on primary care deployment. As an emerging company with overlapping AI retinal screening capabilities, it competes with Vitazi.ai's Vitazi-DR product.
• LumineticsCore (formerly EyeArt competitor) — Iris Health: LumineticsCore is an FDA-cleared autonomous AI for DR screening emerging from the same IDx lineage. Comparable to Vitazi-DR in clinical workflow and target setting, it represents an emerging competitor in autonomous diabetic retinopathy detection.

Others

• Centric Health (Oculo): Centric Health, through its Oculo platform, provides clinical communication and image-sharing services for eye care professionals. It is thematically adjacent to Vitazi.ai's Image Hub in connecting fragmented eye care workflows and provider collaboration, though it does not directly compete on AI-driven retinal analysis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/VitaziAi
• Facebookfacebook.com/vitaziai
• LinkedInlinkedin.com/company/vitazi-ai

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vitazi.ai